A novel soluble guanylate cyclase activator with reduced risk of hypotension by short‐acting vasodilation

Cinaciguat, a soluble guanylate cyclase (sGC) activator, was under clinical development for use in acute decompensated heart failure (ADHF), but was discontinued due to occurrence of hypotension. We hypothesized that short‐term activation of sGC in ADHF patients would exert a vasodilative effect wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawabe, Toshihiro, Chiba, Toshiki, Kobayashi, Akihiro, Nagasaka, Kosuke, Aihara, Kazuyuki, Takaya, Akiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399102/
https://www.ncbi.nlm.nih.gov/pubmed/30873284
http://dx.doi.org/10.1002/prp2.463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399102/
https://www.ncbi.nlm.nih.gov/pubmed/30873284
http://dx.doi.org/10.1002/prp2.463

Ejemplares similares